HDAC-IN-41

Cat. No.:	HY-147840
CAS No.:	2490309-83-4
Molecular Formula:	$C_{20}H_{22}N_4O_6S$
Molecular Weight:	446.48
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HDAC-IN-41 (Compound 7c) is a selective, orally active class I HDAC inhibitor with IC_{50} values of 0.62, 1.46 and 0.62 μM against HDAC1, HDAC2 and HDAC3, respectively. HDAC-IN-41 shows NO releasing activity[1].		
IC_{50} & Target	HDAC1 0.62 μM (IC_{50})	HDAC3 0.62 μM (IC_{50})	HDAC2 1.46 μM (IC_{50})
In Vitro	HDAC-IN-41 (Compound 7c) shows anti-proliferative activity with IC_{50} values of 0.32 ± 0.06, 0.59 ± 0.09, 0.54 ± 0.05, 1.23 ± 0.06, 2.69 ± 0.15, 0.93 ± 0.08 and 1.03 ± 0.09 μM against HEL, MOLT-4, Jurkat, HeLa, PC-3, HCT116 and A549 cells, respectively [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	HDAC-IN-41 (Compound 7c) (30 mg/kg/d; p.o., 15 days) inhibits tumor growth in a HCT116 xenograft model in nude mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Ding Q, et al. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. Bioorg Chem. 2020 Nov;104:104235.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA